1	Two	_	CD	_	_	3	NMOD	_	_
2	Japanese	_	JJ	_	_	3	NMOD	_	_
3	scientists	_	NNS	_	_	4	SBJ	_	_
4	said	_	VBD	_	_	0	ROOT	_	_
5	they	_	PRP	_	_	6	SBJ	_	_
6	discovered	_	VBD	_	_	4	OBJ	_	_
7	an	_	DT	_	_	8	NMOD	_	_
8	antibody	_	NN	_	_	6	OBJ	_	_
9	that	_	IN	_	_	16	SBJ	_	_
10	,	_	,	_	_	16	P	_	_
11	in	_	IN	_	_	16	LOC	_	_
12	laboratory	_	NN	_	_	14	NMOD	_	_
13	test-tube	_	NN	_	_	14	NMOD	_	_
14	experiments	_	NNS	_	_	11	PMOD	_	_
15	,	_	,	_	_	16	P	_	_
16	kills	_	VBZ	_	_	8	NMOD	_	_
17	AIDS-infected	_	JJ	_	_	18	NMOD	_	_
18	cells	_	NNS	_	_	16	OBJ	_	_
19	while	_	IN	_	_	16	TMP	_	_
20	preserving	_	VBG	_	_	19	SUB	_	_
21	healthy	_	JJ	_	_	22	NMOD	_	_
22	cells	_	NNS	_	_	20	OBJ	_	_
23	.	_	.	_	_	4	P	_	_

1	If	_	IN	_	_	9	ADV	_	_
2	further	_	JJ	_	_	3	NMOD	_	_
3	experiments	_	NNS	_	_	4	SBJ	_	_
4	are	_	VBP	_	_	1	SUB	_	_
5	successful	_	JJ	_	_	4	PRD	_	_
6	,	_	,	_	_	9	P	_	_
7	the	_	DT	_	_	8	NMOD	_	_
8	work	_	NN	_	_	9	SBJ	_	_
9	would	_	MD	_	_	0	ROOT	_	_
10	represent	_	VB	_	_	9	VC	_	_
11	a	_	DT	_	_	13	NMOD	_	_
12	major	_	JJ	_	_	13	NMOD	_	_
13	advance	_	NN	_	_	10	OBJ	_	_
14	in	_	IN	_	_	13	NMOD	_	_
15	research	_	NN	_	_	14	PMOD	_	_
16	on	_	IN	_	_	15	NMOD	_	_
17	acquired	_	VBN	_	_	20	NMOD	_	_
18	immune	_	JJ	_	_	20	NMOD	_	_
19	deficiency	_	NN	_	_	20	NMOD	_	_
20	syndrome	_	NN	_	_	16	PMOD	_	_
21	.	_	.	_	_	9	P	_	_

1	The	_	DT	_	_	3	NMOD	_	_
2	drug	_	NN	_	_	3	NMOD	_	_
3	AZT	_	NNP	_	_	13	SBJ	_	_
4	,	_	,	_	_	3	P	_	_
5	the	_	DT	_	_	7	NMOD	_	_
6	only	_	JJ	_	_	7	NMOD	_	_
7	treatment	_	NN	_	_	3	APPO	_	_
8	currently	_	RB	_	_	7	NMOD	_	_
9	on	_	IN	_	_	8	DEP	_	_
10	the	_	DT	_	_	11	NMOD	_	_
11	market	_	NN	_	_	9	PMOD	_	_
12	,	_	,	_	_	3	P	_	_
13	claims	_	VBZ	_	_	0	ROOT	_	_
14	only	_	RB	_	_	15	ADV	_	_
15	to	_	TO	_	_	13	OPRD	_	_
16	help	_	VB	_	_	15	IM	_	_
17	stop	_	VB	_	_	16	OPRD	_	_
18	the	_	DT	_	_	19	NMOD	_	_
19	spread	_	NN	_	_	17	OBJ	_	_
20	of	_	IN	_	_	19	NMOD	_	_
21	AIDS	_	NNP	_	_	20	PMOD	_	_
22	,	_	,	_	_	15	P	_	_
23	not	_	RB	_	_	15	ADV	_	_
24	to	_	TO	_	_	15	IM	_	_
25	cure	_	VB	_	_	24	IM	_	_
26	it	_	PRP	_	_	25	OBJ	_	_
27	.	_	.	_	_	13	P	_	_

1	But	_	CC	_	_	22	DEP	_	_
2	several	_	JJ	_	_	3	NMOD	_	_
3	analysts	_	NNS	_	_	22	SBJ	_	_
4	and	_	CC	_	_	3	COORD	_	_
5	Japanese	_	JJ	_	_	6	NMOD	_	_
6	scientists	_	NNS	_	_	4	CONJ	_	_
7	familiar	_	JJ	_	_	3	APPO	_	_
8	with	_	IN	_	_	7	AMOD	_	_
9	the	_	DT	_	_	10	NMOD	_	_
10	study	_	NN	_	_	8	PMOD	_	_
11	,	_	,	_	_	10	P	_	_
12	which	_	WDT	_	_	13	SBJ	_	_
13	was	_	VBD	_	_	10	NMOD	_	_
14	announced	_	VBN	_	_	13	VC	_	_
15	at	_	IN	_	_	14	LOC	_	_
16	a	_	DT	_	_	17	NMOD	_	_
17	conference	_	NN	_	_	15	PMOD	_	_
18	in	_	IN	_	_	17	LOC	_	_
19	Nagoya	_	NNP	_	_	18	PMOD	_	_
20	yesterday	_	NN	_	_	14	TMP	_	_
21	,	_	,	_	_	10	P	_	_
22	expressed	_	VBD	_	_	0	ROOT	_	_
23	skepticism	_	NN	_	_	22	OBJ	_	_
24	over	_	IN	_	_	22	ADV	_	_
25	the	_	DT	_	_	26	NMOD	_	_
26	significance	_	NN	_	_	24	PMOD	_	_
27	of	_	IN	_	_	26	NMOD	_	_
28	the	_	DT	_	_	29	NMOD	_	_
29	results	_	NNS	_	_	27	PMOD	_	_
30	.	_	.	_	_	22	P	_	_

1	And	_	CC	_	_	5	DEP	_	_
2	the	_	DT	_	_	3	NMOD	_	_
3	researchers	_	NNS	_	_	5	SBJ	_	_
4	themselves	_	PRP	_	_	3	APPO	_	_
5	acknowledged	_	VBD	_	_	0	ROOT	_	_
6	they	_	PRP	_	_	8	SBJ	_	_
7	still	_	RB	_	_	8	ADV	_	_
8	must	_	MD	_	_	5	OBJ	_	_
9	do	_	VB	_	_	8	VC	_	_
10	much	_	RB	_	_	11	AMOD	_	_
11	more	_	JJR	_	_	12	NMOD	_	_
12	work	_	NN	_	_	9	OBJ	_	_
13	before	_	IN	_	_	9	TMP	_	_
14	they	_	PRP	_	_	15	SBJ	_	_
15	can	_	MD	_	_	13	SUB	_	_
16	say	_	VB	_	_	15	VC	_	_
17	whether	_	IN	_	_	16	OBJ	_	_
18	the	_	DT	_	_	19	NMOD	_	_
19	treatment	_	NN	_	_	20	SBJ	_	_
20	would	_	MD	_	_	17	SUB	_	_
21	actually	_	RB	_	_	20	ADV	_	_
22	cure	_	VB	_	_	20	VC	_	_
23	humans	_	NNS	_	_	22	OBJ	_	_
24	.	_	.	_	_	5	P	_	_

1	Shin	_	NNP	_	_	2	NAME	_	_
2	Yonehara	_	NNP	_	_	16	SBJ	_	_
3	,	_	,	_	_	2	P	_	_
4	a	_	DT	_	_	6	NMOD	_	_
5	research	_	NN	_	_	6	NMOD	_	_
6	scientist	_	NN	_	_	2	APPO	_	_
7	at	_	IN	_	_	6	LOC	_	_
8	the	_	DT	_	_	11	NMOD	_	_
9	Tokyo	_	NNP	_	_	11	NAME	_	_
10	Metropolitan	_	NNP	_	_	11	NAME	_	_
11	Institute	_	NNP	_	_	7	PMOD	_	_
12	of	_	IN	_	_	11	NMOD	_	_
13	Medical	_	NNP	_	_	14	NAME	_	_
14	Science	_	NNP	_	_	12	PMOD	_	_
15	,	_	,	_	_	2	P	_	_
16	said	_	VBD	_	_	0	ROOT	_	_
17	the	_	DT	_	_	18	NMOD	_	_
18	antibody	_	NN	_	_	21	SBJ	_	_
19	he	_	PRP	_	_	20	SBJ	_	_
20	discovered	_	VBD	_	_	18	NMOD	_	_
21	works	_	VBZ	_	_	16	OBJ	_	_
22	by	_	IN	_	_	21	MNR	_	_
23	recognizing	_	VBG	_	_	22	PMOD	_	_
24	an	_	DT	_	_	25	NMOD	_	_
25	antigen	_	NN	_	_	23	OBJ	_	_
26	called	_	VBN	_	_	25	APPO	_	_
27	a	_	DT	_	_	28	NMOD	_	_
28	Fas-antigen	_	NN	_	_	26	OPRD	_	_
29	,	_	,	_	_	25	P	_	_
30	which	_	WDT	_	_	31	SBJ	_	_
31	is	_	VBZ	_	_	25	NMOD	_	_
32	characteristic	_	JJ	_	_	31	PRD	_	_
33	of	_	IN	_	_	32	AMOD	_	_
34	an	_	DT	_	_	36	NMOD	_	_
35	infected	_	JJ	_	_	36	NMOD	_	_
36	cell	_	NN	_	_	33	PMOD	_	_
37	.	_	.	_	_	16	P	_	_

1	The	_	DT	_	_	2	NMOD	_	_
2	antibody	_	NN	_	_	4	SBJ	_	_
3	then	_	RB	_	_	4	TMP	_	_
4	kills	_	VBZ	_	_	0	ROOT	_	_
5	the	_	DT	_	_	6	NMOD	_	_
6	cell	_	NN	_	_	4	OBJ	_	_
7	.	_	.	_	_	4	P	_	_

1	Dr.	_	NNP	_	_	2	TITLE	_	_
2	Yonehara	_	NNP	_	_	13	SBJ	_	_
3	and	_	CC	_	_	2	COORD	_	_
4	his	_	PRP$	_	_	5	NMOD	_	_
5	partner	_	NN	_	_	3	CONJ	_	_
6	,	_	,	_	_	5	P	_	_
7	Nobuyuki	_	NNP	_	_	8	NAME	_	_
8	Kobayashi	_	NNP	_	_	5	APPO	_	_
9	of	_	IN	_	_	8	NMOD	_	_
10	Yamaguchi	_	NNP	_	_	11	NAME	_	_
11	University	_	NNP	_	_	9	PMOD	_	_
12	,	_	,	_	_	5	P	_	_
13	said	_	VBD	_	_	0	ROOT	_	_
14	their	_	PRP$	_	_	15	NMOD	_	_
15	experiments	_	NNS	_	_	16	SBJ	_	_
16	showed	_	VBD	_	_	13	OBJ	_	_
17	that	_	IN	_	_	16	OBJ	_	_
18	the	_	DT	_	_	19	NMOD	_	_
19	antibody	_	NN	_	_	20	SBJ	_	_
20	wiped	_	VBD	_	_	17	SUB	_	_
21	out	_	RP	_	_	20	PRT	_	_
22	an	_	DT	_	_	23	NMOD	_	_
23	average	_	NN	_	_	20	OBJ	_	_
24	of	_	IN	_	_	23	NMOD	_	_
25	60	_	CD	_	_	26	NMOD	_	_
26	%	_	NN	_	_	24	PMOD	_	_
27	of	_	IN	_	_	26	NMOD	_	_
28	AIDS-infected	_	JJ	_	_	29	NMOD	_	_
29	cells	_	NNS	_	_	27	PMOD	_	_
30	within	_	IN	_	_	20	TMP	_	_
31	three	_	CD	_	_	32	NMOD	_	_
32	days	_	NNS	_	_	30	PMOD	_	_
33	.	_	.	_	_	13	P	_	_

1	In	_	IN	_	_	8	LOC	_	_
2	some	_	DT	_	_	1	PMOD	_	_
3	of	_	IN	_	_	2	NMOD	_	_
4	the	_	DT	_	_	5	NMOD	_	_
5	experiments	_	NNS	_	_	3	PMOD	_	_
6	,	_	,	_	_	8	P	_	_
7	it	_	PRP	_	_	8	SBJ	_	_
8	killed	_	VBD	_	_	17	OBJ	_	_
9	almost	_	RB	_	_	13	NMOD	_	_
10	all	_	PDT	_	_	9	DEP	_	_
11	the	_	DT	_	_	13	NMOD	_	_
12	infected	_	JJ	_	_	13	NMOD	_	_
13	cells	_	NNS	_	_	8	OBJ	_	_
14	,	_	,	_	_	17	P	_	_
15	the	_	DT	_	_	16	NMOD	_	_
16	researchers	_	NNS	_	_	17	SBJ	_	_
17	said	_	VBD	_	_	0	ROOT	_	_
18	.	_	.	_	_	17	P	_	_

1	Meanwhile	_	RB	_	_	11	ADV	_	_
2	,	_	,	_	_	11	P	_	_
3	fewer	_	JJR	_	_	5	DEP	_	_
4	than	_	IN	_	_	5	DEP	_	_
5	10	_	CD	_	_	6	NMOD	_	_
6	%	_	NN	_	_	11	SBJ	_	_
7	of	_	IN	_	_	6	NMOD	_	_
8	the	_	DT	_	_	10	NMOD	_	_
9	healthy	_	JJ	_	_	10	NMOD	_	_
10	cells	_	NNS	_	_	7	PMOD	_	_
11	were	_	VBD	_	_	0	ROOT	_	_
12	killed	_	VBN	_	_	11	VC	_	_
13	.	_	.	_	_	11	P	_	_

1	The	_	DT	_	_	2	NMOD	_	_
2	two	_	CD	_	_	3	SBJ	_	_
3	said	_	VBD	_	_	0	ROOT	_	_
4	they	_	PRP	_	_	5	SBJ	_	_
5	must	_	MD	_	_	3	OBJ	_	_
6	still	_	RB	_	_	7	ADV	_	_
7	do	_	VB	_	_	5	VC	_	_
8	more	_	JJR	_	_	10	NMOD	_	_
9	laboratory	_	NN	_	_	10	NMOD	_	_
10	tests	_	NNS	_	_	7	OBJ	_	_
11	,	_	,	_	_	7	P	_	_
12	then	_	RB	_	_	7	COORD	_	_
13	experiment	_	NN	_	_	12	COORD	_	_
14	on	_	IN	_	_	13	ADV	_	_
15	animals	_	NNS	_	_	14	PMOD	_	_
16	.	_	.	_	_	3	P	_	_

1	They	_	PRP	_	_	2	SBJ	_	_
2	said	_	VBD	_	_	0	ROOT	_	_
3	they	_	PRP	_	_	4	SBJ	_	_
4	hoped	_	VBD	_	_	2	OBJ	_	_
5	to	_	TO	_	_	4	OPRD	_	_
6	conduct	_	VB	_	_	5	IM	_	_
7	tests	_	NNS	_	_	6	OBJ	_	_
8	on	_	IN	_	_	6	ADV	_	_
9	human	_	JJ	_	_	10	NMOD	_	_
10	patients	_	NNS	_	_	8	PMOD	_	_
11	in	_	IN	_	_	10	LOC	_	_
12	the	_	DT	_	_	13	NMOD	_	_
13	U.S.	_	NNP	_	_	11	PMOD	_	_
14	by	_	IN	_	_	6	TMP	_	_
15	late	_	JJ	_	_	17	NMOD	_	_
16	next	_	JJ	_	_	17	NMOD	_	_
17	year	_	NN	_	_	14	PMOD	_	_
18	.	_	.	_	_	2	P	_	_

1	Japan	_	NNP	_	_	2	SBJ	_	_
2	does	_	VBZ	_	_	17	OBJ	_	_
3	n't	_	RB	_	_	2	ADV	_	_
4	have	_	VB	_	_	2	VC	_	_
5	enough	_	JJ	_	_	7	NMOD	_	_
6	AIDS	_	NNP	_	_	7	NMOD	_	_
7	patients	_	NNS	_	_	4	OBJ	_	_
8	to	_	TO	_	_	7	NMOD	_	_
9	do	_	VB	_	_	8	IM	_	_
10	significant	_	JJ	_	_	11	NMOD	_	_
11	experimentation	_	NN	_	_	9	OBJ	_	_
12	in	_	IN	_	_	9	LOC	_	_
13	that	_	DT	_	_	14	NMOD	_	_
14	country	_	NN	_	_	12	PMOD	_	_
15	,	_	,	_	_	17	P	_	_
16	they	_	PRP	_	_	17	SBJ	_	_
17	said	_	VBD	_	_	0	ROOT	_	_
18	.	_	.	_	_	17	P	_	_

1	The	_	DT	_	_	2	NMOD	_	_
2	announcement	_	NN	_	_	3	SBJ	_	_
3	got	_	VBD	_	_	0	ROOT	_	_
4	wide	_	JJ	_	_	5	NMOD	_	_
5	exposure	_	NN	_	_	3	OBJ	_	_
6	in	_	IN	_	_	3	LOC	_	_
7	the	_	DT	_	_	9	NMOD	_	_
8	Japanese	_	JJ	_	_	9	NMOD	_	_
9	media	_	NNS	_	_	6	PMOD	_	_
10	,	_	,	_	_	3	P	_	_
11	and	_	CC	_	_	3	COORD	_	_
12	even	_	RB	_	_	13	ADV	_	_
13	moved	_	VBD	_	_	11	CONJ	_	_
14	some	_	DT	_	_	16	NMOD	_	_
15	pharmaceutical	_	JJ	_	_	16	NMOD	_	_
16	stocks	_	NNS	_	_	13	OBJ	_	_
17	yesterday	_	NN	_	_	13	TMP	_	_
18	.	_	.	_	_	3	P	_	_

1	But	_	CC	_	_	26	DEP	_	_
2	Takashi	_	NNP	_	_	3	NAME	_	_
3	Kitamura	_	NNP	_	_	26	SBJ	_	_
4	,	_	,	_	_	3	P	_	_
5	director	_	NN	_	_	3	APPO	_	_
6	of	_	IN	_	_	5	NMOD	_	_
7	the	_	DT	_	_	9	NMOD	_	_
8	biology	_	NN	_	_	9	NMOD	_	_
9	department	_	NN	_	_	6	PMOD	_	_
10	at	_	IN	_	_	9	LOC	_	_
11	Japan	_	NNP	_	_	14	NMOD	_	_
12	's	_	POS	_	_	11	SUFFIX	_	_
13	National	_	NNP	_	_	14	NAME	_	_
14	Institute	_	NNP	_	_	10	PMOD	_	_
15	of	_	IN	_	_	14	NMOD	_	_
16	Health	_	NNP	_	_	15	PMOD	_	_
17	and	_	CC	_	_	5	COORD	_	_
18	secretary	_	NN	_	_	17	CONJ	_	_
19	of	_	IN	_	_	18	NMOD	_	_
20	the	_	DT	_	_	21	NMOD	_	_
21	government	_	NN	_	_	24	NMOD	_	_
22	's	_	POS	_	_	21	SUFFIX	_	_
23	AIDS-research	_	JJ	_	_	24	NMOD	_	_
24	center	_	NN	_	_	19	PMOD	_	_
25	,	_	,	_	_	3	P	_	_
26	said	_	VBD	_	_	0	ROOT	_	_
27	,	_	,	_	_	26	P	_	_
28	``	_	``	_	_	26	P	_	_
29	I	_	PRP	_	_	30	SBJ	_	_
30	'm	_	VBP	_	_	26	OBJ	_	_
31	not	_	RB	_	_	30	ADV	_	_
32	so	_	RB	_	_	33	AMOD	_	_
33	optimistic	_	JJ	_	_	30	PRD	_	_
34	of	_	IN	_	_	33	AMOD	_	_
35	its	_	PRP$	_	_	37	NMOD	_	_
36	future	_	JJ	_	_	37	NMOD	_	_
37	use	_	NN	_	_	34	PMOD	_	_
38	in	_	IN	_	_	37	LOC	_	_
39	therapeutic	_	JJ	_	_	40	NMOD	_	_
40	methods	_	NNS	_	_	38	PMOD	_	_
41	.	_	.	_	_	26	P	_	_
42	''	_	''	_	_	26	P	_	_

1	He	_	PRP	_	_	2	SBJ	_	_
2	said	_	VBD	_	_	0	ROOT	_	_
3	some	_	DT	_	_	5	NMOD	_	_
4	infected	_	JJ	_	_	5	NMOD	_	_
5	cells	_	NNS	_	_	6	SBJ	_	_
6	may	_	MD	_	_	2	OBJ	_	_
7	not	_	RB	_	_	6	ADV	_	_
8	have	_	VB	_	_	6	VC	_	_
9	the	_	DT	_	_	11	NMOD	_	_
10	relevant	_	JJ	_	_	11	NMOD	_	_
11	antigen	_	NN	_	_	8	OBJ	_	_
12	and	_	CC	_	_	6	COORD	_	_
13	so	_	RB	_	_	14	ADV	_	_
14	would	_	MD	_	_	12	CONJ	_	_
15	n't	_	RB	_	_	14	ADV	_	_
16	be	_	VB	_	_	14	VC	_	_
17	killed	_	VBN	_	_	16	VC	_	_
18	even	_	RB	_	_	19	PMOD	_	_
19	after	_	IN	_	_	17	TMP	_	_
20	exposure	_	NN	_	_	19	PMOD	_	_
21	to	_	TO	_	_	20	NMOD	_	_
22	the	_	DT	_	_	23	NMOD	_	_
23	antibody	_	NN	_	_	21	PMOD	_	_
24	.	_	.	_	_	2	P	_	_

1	``	_	``	_	_	11	P	_	_
2	The	_	DT	_	_	3	NMOD	_	_
3	results	_	NNS	_	_	4	SBJ	_	_
4	seem	_	VBP	_	_	11	OBJ	_	_
5	to	_	TO	_	_	4	OPRD	_	_
6	be	_	VB	_	_	5	IM	_	_
7	very	_	RB	_	_	8	AMOD	_	_
8	premature	_	JJ	_	_	6	PRD	_	_
9	,	_	,	_	_	11	P	_	_
10	''	_	''	_	_	11	P	_	_
11	said	_	VBD	_	_	0	ROOT	_	_
12	Mitsuru	_	NNP	_	_	13	NAME	_	_
13	Miyata	_	NNP	_	_	11	SBJ	_	_
14	,	_	,	_	_	13	P	_	_
15	editor	_	NN	_	_	13	APPO	_	_
16	of	_	IN	_	_	15	NMOD	_	_
17	Nikkei	_	NNP	_	_	18	NAME	_	_
18	Biotechnology	_	NNP	_	_	16	PMOD	_	_
19	,	_	,	_	_	18	P	_	_
20	a	_	DT	_	_	24	NMOD	_	_
21	leading	_	VBG	_	_	24	NMOD	_	_
22	Japanese	_	JJ	_	_	24	NMOD	_	_
23	industry	_	NN	_	_	24	NMOD	_	_
24	newsletter	_	NN	_	_	18	APPO	_	_
25	.	_	.	_	_	11	P	_	_

1	Dr.	_	NNP	_	_	2	TITLE	_	_
2	Kobayashi	_	NNP	_	_	3	SBJ	_	_
3	responded	_	VBD	_	_	0	ROOT	_	_
4	that	_	IN	_	_	3	OBJ	_	_
5	he	_	PRP	_	_	6	SBJ	_	_
6	thought	_	VBD	_	_	4	SUB	_	_
7	the	_	DT	_	_	8	NMOD	_	_
8	antibody	_	NN	_	_	9	SBJ	_	_
9	could	_	MD	_	_	6	OBJ	_	_
10	potentially	_	RB	_	_	9	ADV	_	_
11	kill	_	VB	_	_	9	VC	_	_
12	all	_	DT	_	_	14	NMOD	_	_
13	infected	_	JJ	_	_	14	NMOD	_	_
14	cells	_	NNS	_	_	11	OBJ	_	_
15	.	_	.	_	_	3	P	_	_

1	But	_	CC	_	_	6	DEP	_	_
2	he	_	PRP	_	_	6	SBJ	_	_
3	and	_	CC	_	_	2	COORD	_	_
4	Dr.	_	NNP	_	_	5	TITLE	_	_
5	Yonehara	_	NNP	_	_	3	CONJ	_	_
6	said	_	VBD	_	_	0	ROOT	_	_
7	there	_	EX	_	_	8	SBJ	_	_
8	were	_	VBD	_	_	6	OBJ	_	_
9	still	_	RB	_	_	8	ADV	_	_
10	several	_	JJ	_	_	11	NMOD	_	_
11	uncertainties	_	NNS	_	_	8	PRD	_	_
12	,	_	,	_	_	11	P	_	_
13	particularly	_	RB	_	_	11	NMOD	_	_
14	regarding	_	VBG	_	_	13	DEP	_	_
15	possible	_	JJ	_	_	17	NMOD	_	_
16	side	_	NN	_	_	17	NMOD	_	_
17	effects	_	NNS	_	_	14	PMOD	_	_
18	.	_	.	_	_	6	P	_	_

1	``	_	``	_	_	23	P	_	_
2	Our	_	PRP$	_	_	3	NMOD	_	_
3	antibody	_	NN	_	_	5	SBJ	_	_
4	specifically	_	RB	_	_	5	ADV	_	_
5	killed	_	VBD	_	_	23	OBJ	_	_
6	infected	_	JJ	_	_	7	NMOD	_	_
7	cells	_	NNS	_	_	5	OBJ	_	_
8	at	_	IN	_	_	5	MNR	_	_
9	a	_	DT	_	_	12	NMOD	_	_
10	very	_	RB	_	_	11	AMOD	_	_
11	low	_	JJ	_	_	12	NMOD	_	_
12	dose	_	NN	_	_	8	PMOD	_	_
13	,	_	,	_	_	5	P	_	_
14	but	_	CC	_	_	5	COORD	_	_
15	it	_	PRP	_	_	16	SBJ	_	_
16	can	_	MD	_	_	14	CONJ	_	_
17	also	_	RB	_	_	16	ADV	_	_
18	kill	_	VB	_	_	16	VC	_	_
19	other	_	JJ	_	_	20	NMOD	_	_
20	cells	_	NNS	_	_	18	OBJ	_	_
21	,	_	,	_	_	23	P	_	_
22	''	_	''	_	_	23	P	_	_
23	said	_	VBD	_	_	0	ROOT	_	_
24	Dr.	_	NNP	_	_	25	TITLE	_	_
25	Yonehara	_	NNP	_	_	23	SBJ	_	_
26	.	_	.	_	_	23	P	_	_

1	``	_	``	_	_	3	P	_	_
2	We	_	PRP	_	_	3	SBJ	_	_
3	do	_	VBP	_	_	0	ROOT	_	_
4	n't	_	RB	_	_	3	ADV	_	_
5	know	_	VB	_	_	3	VC	_	_
6	the	_	DT	_	_	7	NMOD	_	_
7	effect	_	NN	_	_	5	OBJ	_	_
8	of	_	IN	_	_	7	NMOD	_	_
9	our	_	PRP$	_	_	10	NMOD	_	_
10	antibody	_	NN	_	_	8	PMOD	_	_
11	on	_	IN	_	_	7	NMOD	_	_
12	the	_	DT	_	_	14	NMOD	_	_
13	human	_	JJ	_	_	14	NMOD	_	_
14	body	_	NN	_	_	11	PMOD	_	_
15	.	_	.	_	_	3	P	_	_
16	''	_	''	_	_	3	P	_	_

1	AIDS	_	NNP	_	_	2	SBJ	_	_
2	is	_	VBZ	_	_	0	ROOT	_	_
3	n't	_	RB	_	_	2	ADV	_	_
4	considered	_	VBN	_	_	2	VC	_	_
5	a	_	DT	_	_	7	NMOD	_	_
6	widespread	_	JJ	_	_	7	NMOD	_	_
7	problem	_	NN	_	_	4	OPRD	_	_
8	in	_	IN	_	_	7	LOC	_	_
9	Japan	_	NNP	_	_	8	PMOD	_	_
10	--	_	:	_	_	2	P	_	_
11	the	_	DT	_	_	12	NMOD	_	_
12	government	_	NN	_	_	13	SBJ	_	_
13	reports	_	VBZ	_	_	2	COORD	_	_
14	about	_	IN	_	_	15	DEP	_	_
15	1,000	_	CD	_	_	17	NMOD	_	_
16	known	_	VBN	_	_	17	NMOD	_	_
17	carriers	_	NNS	_	_	13	OBJ	_	_
18	of	_	IN	_	_	17	NMOD	_	_
19	the	_	DT	_	_	20	NMOD	_	_
20	virus	_	NN	_	_	18	PMOD	_	_
21	--	_	:	_	_	13	P	_	_
22	but	_	CC	_	_	13	COORD	_	_
23	many	_	JJ	_	_	24	NMOD	_	_
24	companies	_	NNS	_	_	25	SBJ	_	_
25	have	_	VBP	_	_	22	CONJ	_	_
26	poured	_	VBN	_	_	25	VC	_	_
27	substantial	_	JJ	_	_	28	NMOD	_	_
28	resources	_	NNS	_	_	26	OBJ	_	_
29	into	_	IN	_	_	26	ADV	_	_
30	research	_	NN	_	_	29	PMOD	_	_
31	in	_	IN	_	_	26	TMP	_	_
32	recent	_	JJ	_	_	33	NMOD	_	_
33	years	_	NNS	_	_	31	PMOD	_	_
34	,	_	,	_	_	26	P	_	_
35	hoping	_	VBG	_	_	26	ADV	_	_
36	to	_	TO	_	_	35	OPRD	_	_
37	cash	_	VB	_	_	36	IM	_	_
38	in	_	RP	_	_	37	PRT	_	_
39	on	_	IN	_	_	37	ADV	_	_
40	a	_	DT	_	_	42	NMOD	_	_
41	possible	_	JJ	_	_	42	NMOD	_	_
42	cure	_	NN	_	_	39	PMOD	_	_
43	.	_	.	_	_	2	P	_	_

1	Dr.	_	NNP	_	_	2	TITLE	_	_
2	Kitamura	_	NNP	_	_	3	SBJ	_	_
3	said	_	VBD	_	_	0	ROOT	_	_
4	about	_	IN	_	_	5	DEP	_	_
5	35	_	CD	_	_	6	NMOD	_	_
6	projects	_	NNS	_	_	7	SBJ	_	_
7	are	_	VBP	_	_	3	OBJ	_	_
8	currently	_	RB	_	_	7	TMP	_	_
9	under	_	IN	_	_	7	PRD	_	_
10	way	_	NN	_	_	9	PMOD	_	_
11	in	_	IN	_	_	7	LOC	_	_
12	Japan	_	NNP	_	_	11	PMOD	_	_
13	,	_	,	_	_	7	P	_	_
14	and	_	CC	_	_	7	COORD	_	_
15	that	_	IN	_	_	14	CONJ	_	_
16	Japanese	_	JJ	_	_	17	NMOD	_	_
17	researchers	_	NNS	_	_	22	SBJ	_	_
18	in	_	IN	_	_	17	TMP	_	_
19	the	_	DT	_	_	21	NMOD	_	_
20	past	_	JJ	_	_	21	NMOD	_	_
21	year	_	NN	_	_	18	PMOD	_	_
22	have	_	VBP	_	_	15	SUB	_	_
23	made	_	VBN	_	_	22	VC	_	_
24	available	_	JJ	_	_	23	OPRD	_	_
25	three	_	CD	_	_	27	NMOD	_	_
26	possible	_	JJ	_	_	27	NMOD	_	_
27	cures	_	NNS	_	_	23	OBJ	_	_
28	to	_	TO	_	_	24	AMOD	_	_
29	American	_	JJ	_	_	30	NMOD	_	_
30	researchers	_	NNS	_	_	28	PMOD	_	_
31	for	_	IN	_	_	24	AMOD	_	_
32	clinical	_	JJ	_	_	33	NMOD	_	_
33	tests	_	NNS	_	_	31	PMOD	_	_
34	.	_	.	_	_	3	P	_	_

1	He	_	PRP	_	_	2	SBJ	_	_
2	said	_	VBD	_	_	0	ROOT	_	_
3	that	_	IN	_	_	2	OBJ	_	_
4	when	_	WRB	_	_	10	TMP	_	_
5	scientists	_	NNS	_	_	10	SBJ	_	_
6	from	_	IN	_	_	5	NMOD	_	_
7	the	_	DT	_	_	9	NMOD	_	_
8	two	_	CD	_	_	9	NMOD	_	_
9	countries	_	NNS	_	_	6	PMOD	_	_
10	meet	_	VBP	_	_	20	TMP	_	_
11	again	_	RB	_	_	10	ADV	_	_
12	in	_	IN	_	_	10	TMP	_	_
13	January	_	NNP	_	_	12	PMOD	_	_
14	in	_	IN	_	_	10	LOC	_	_
15	New	_	NNP	_	_	16	NAME	_	_
16	Orleans	_	NNP	_	_	14	PMOD	_	_
17	,	_	,	_	_	20	P	_	_
18	the	_	DT	_	_	19	NMOD	_	_
19	Japanese	_	NNP	_	_	20	SBJ	_	_
20	will	_	MD	_	_	3	SUB	_	_
21	present	_	VB	_	_	20	VC	_	_
22	at	_	IN	_	_	24	DEP	_	_
23	least	_	JJS	_	_	24	DEP	_	_
24	three	_	CD	_	_	26	NMOD	_	_
25	more	_	JJR	_	_	24	AMOD	_	_
26	drugs	_	NNS	_	_	21	OBJ	_	_
27	for	_	IN	_	_	21	ADV	_	_
28	human	_	JJ	_	_	29	NMOD	_	_
29	testing	_	NN	_	_	27	PMOD	_	_
30	.	_	.	_	_	2	P	_	_

1	AZT	_	NNP	_	_	2	SBJ	_	_
2	is	_	VBZ	_	_	0	ROOT	_	_
3	the	_	DT	_	_	4	NMOD	_	_
4	world	_	NN	_	_	8	NMOD	_	_
5	's	_	POS	_	_	4	SUFFIX	_	_
6	only	_	JJ	_	_	8	NMOD	_	_
7	prescription	_	NN	_	_	8	NMOD	_	_
8	medicine	_	NN	_	_	2	PRD	_	_
9	approved	_	VBN	_	_	8	APPO	_	_
10	for	_	IN	_	_	9	ADV	_	_
11	treating	_	VBG	_	_	10	PMOD	_	_
12	the	_	DT	_	_	13	NMOD	_	_
13	disease	_	NN	_	_	11	OBJ	_	_
14	.	_	.	_	_	2	P	_	_

1	Wellcome	_	NNP	_	_	2	NAME	_	_
2	PLC	_	NNP	_	_	10	SBJ	_	_
3	,	_	,	_	_	2	P	_	_
4	a	_	DT	_	_	8	NMOD	_	_
5	major	_	JJ	_	_	8	NMOD	_	_
6	British	_	JJ	_	_	8	NMOD	_	_
7	pharmaceutical	_	NN	_	_	8	NMOD	_	_
8	maker	_	NN	_	_	2	APPO	_	_
9	,	_	,	_	_	2	P	_	_
10	sells	_	VBZ	_	_	0	ROOT	_	_
11	the	_	DT	_	_	12	NMOD	_	_
12	drug	_	NN	_	_	10	OBJ	_	_
13	under	_	IN	_	_	10	MNR	_	_
14	the	_	DT	_	_	15	NMOD	_	_
15	name	_	NN	_	_	13	PMOD	_	_
16	Retrovir	_	NNP	_	_	15	APPO	_	_
17	.	_	.	_	_	10	P	_	_

1	A	_	DT	_	_	3	NMOD	_	_
2	Wellcome	_	NNP	_	_	3	NMOD	_	_
3	spokesman	_	NN	_	_	4	SBJ	_	_
4	declined	_	VBD	_	_	0	ROOT	_	_
5	to	_	TO	_	_	4	OPRD	_	_
6	comment	_	VB	_	_	5	IM	_	_
7	on	_	IN	_	_	6	ADV	_	_
8	the	_	DT	_	_	9	NMOD	_	_
9	discovery	_	NN	_	_	7	PMOD	_	_
10	of	_	IN	_	_	9	NMOD	_	_
11	the	_	DT	_	_	12	NMOD	_	_
12	antibody	_	NN	_	_	10	PMOD	_	_
13	in	_	IN	_	_	9	LOC	_	_
14	Japan	_	NNP	_	_	13	PMOD	_	_
15	.	_	.	_	_	4	P	_	_

1	But	_	CC	_	_	15	DEP	_	_
2	Andrew	_	NNP	_	_	3	NAME	_	_
3	Porter	_	NNP	_	_	15	SBJ	_	_
4	,	_	,	_	_	3	P	_	_
5	a	_	DT	_	_	7	NMOD	_	_
6	drug-industry	_	NN	_	_	7	NMOD	_	_
7	analyst	_	NN	_	_	3	APPO	_	_
8	at	_	IN	_	_	7	LOC	_	_
9	Nikko	_	NNP	_	_	10	NAME	_	_
10	Securities	_	NNPS	_	_	8	PMOD	_	_
11	Co.	_	NNP	_	_	10	POSTHON	_	_
12	in	_	IN	_	_	10	LOC	_	_
13	London	_	NNP	_	_	12	PMOD	_	_
14	,	_	,	_	_	3	P	_	_
15	said	_	VBD	_	_	0	ROOT	_	_
16	if	_	IN	_	_	25	ADV	_	_
17	the	_	DT	_	_	18	NMOD	_	_
18	product	_	NN	_	_	19	SBJ	_	_
19	were	_	VBD	_	_	16	SUB	_	_
20	to	_	TO	_	_	19	VC	_	_
21	be	_	VB	_	_	20	IM	_	_
22	successfully	_	RB	_	_	23	MNR	_	_
23	developed	_	VBN	_	_	21	VC	_	_
24	it	_	PRP	_	_	25	SBJ	_	_
25	would	_	MD	_	_	15	OBJ	_	_
26	represent	_	VB	_	_	25	VC	_	_
27	``	_	``	_	_	26	P	_	_
28	a	_	DT	_	_	30	NMOD	_	_
29	potential	_	JJ	_	_	30	NMOD	_	_
30	threat	_	NN	_	_	26	OBJ	_	_
31	to	_	TO	_	_	30	NMOD	_	_
32	the	_	DT	_	_	34	NMOD	_	_
33	long-term	_	JJ	_	_	34	NMOD	_	_
34	viability	_	NN	_	_	31	PMOD	_	_
35	of	_	IN	_	_	34	NMOD	_	_
36	Retrovir	_	NNP	_	_	35	PMOD	_	_
37	.	_	.	_	_	15	P	_	_

